Physician profile
David Baxter
NPI 1477932762
$961.82
in general payments reported to CMS, 2019-2025
13 companies · $407 in 2025
The $407 reported for 2025 was more than what 80% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $139 · 2021: $52.04 · 2022: $23.16 · 2023: $107 · 2024: $121 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $193.68 | 2023-2025 | Gel-One Cross-Linked Hyaluronate |
| Pacira Therapeutics, INC. | $173.39 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $126.10 | 2025 | |
| Fidia Pharma USA INC. | $120.33 | 2019-2025 | Hymovis, Triluron |
| Depuy Synthes Sales INC. | $100.21 | 2023-2025 | Monovisc, Orthovisc |
| Vertex Pharmaceuticals Incorporated | $60.14 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $59.12 | 2019-2025 | Euflexxa |
| Kyowa Kirin, INC. | $29.39 | 2024 | Crysvita |
| Synergy Orthopedics, LLC | $24.15 | 2019 | |
| Jazz Pharmaceuticals INC. | $23.34 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.16 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.98 | 2023 | Zilretta, Iovera |
| Sanofi-Aventis U.S. LLC | $11.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Baxter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.